Patent ID: 9060969
Filing Date: 2015-06-23
Classification: A61K,A61L,A61P

Abstract:
1. An extracellular matrix (ECM) composition for treating post-operative atrial fibrillation, comprising: an ECM scaffold comprising sterilized, acellular mesothelial tissue, said mesothelial tissue comprising a pre-processing dry weight transforming growth factor beta (TGF-β) content of at least 5.5 pg/mg and a pre-processing dry weight basic fibroblast growth factor (bFGF) content of at least 30 pg/mg, said mesothelial tissue being contemporaneously sterilized and decellularized by introducing said mesothelial tissue into a reactor pressure vessel, introducing at least a first sterilant comprising carbon dioxide (CO wherein said steps of introducing said CO wherein said mesothelial tissue is rendered at least 96% acellular, said mesothelial tissue further comprising a post-processing dry weight TGF-β content of at least 2.8 pg/mg, and a post-processing dry weight bFGF content of at least 19 pg/mg, and wherein, when said ECM scaffold is administered to damaged myocardial tissue of a subject, said ECM scaffold modulates inflammation of said damaged myocardial tissue induces myofibroblast proliferation and angiogenesis and, thereby, bioremodeling and regeneration of new myocardium tissue, whereby said ECM scaffold modulates electrical activity of said subject's heart.